Trial Profile
MinPAC: A Phase II, International Open Label Trial of Minnelide™ in Patients With Refractory Pancreatic Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Minnelide (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- Acronyms MinPAC
- 01 Sep 2020 Status changed from active, no longer recruiting to completed.
- 24 Apr 2020 Planned End Date changed from 31 Mar 2020 to 31 May 2020.
- 24 Apr 2020 Planned primary completion date changed from 31 Mar 2020 to 31 May 2020.